August 2012 Issue of MMM
AUGUST 2012 issue
Obamacare could cost the industry $140 billion—not exactly a windfall
Merck's Januvia raced to diabetes dominance in many countries. It's a different game for combination products and in emerging markets.
Brazilians and Mexicans have enjoyed economic growth and with it, are more prone to chronic disease. But can they afford medications?Why market access factors can ...
The MM&M Awards are just weeks away. Here are the finalists for this year's awards, who were chosen by over 100 top industry leaders and ...
Cavan Redmond, CEO, WebMD
Incivek and Victrelis changed the standard of care for treating hepatitis C. But they're not in the lead of a second generation of treatments
Most stakeholders have little or no knowledge of the Act's 1,500 pages of specifics or their implications
Public education remains key to the fight against HIV. The new quick test can be a useful aid in this fight
The winner of Sanofi's second Data Design Diabetes Innovation Challenge was a community-focused proposition that focuses on face-to-face interactions
After three years of wrangling, drug companies can again offer co-pay coupons in Massachusetts.
GlaxoSmithKline will pay $3 billion to settle charges that it promoted antidepressants Paxil and Wellbutrin for unindicated uses and withheld safety data on diabetes drug ...
News on Lundbeck, Pfizer and Johnson & Johnson
Med Ed Report
CME providers may see a modest uptick in funding from the FDA's new safety plan for extended-release and long-acting opioids but may be hard-pressed to ...
The US Justice Department, as part of its record $3-billion settlement with GlaxoSmithKline, said the drugmaker employed ostensibly scientific meetings to expand the market for ...
Researchers found use of electronic health records (EHRs) over three years does not ensure successful use for improving diabetes care.
In an effort to shore up their reputations, pharma and professional publishers have crafted an accountability plan.
The American Heart Association's publications are now fully mobile.
News on Quadrant Health, Springer Science + Business Media, and The American Journal of Preventive Medicine
How can pharma marketers strategically and safely use digital to reach customers?
A new online medical contest is progressing from the diagnosis of minor ailments to cancer screening.
Diabetes tech firm Medtronic rolled out a Facebook strategy to help diabetes patients share milestones.
News on iHealth, Deloitte, eMarketer and Sharecard
An advocacy group wants Merck to back away from a recent Children's Claritin promotion
Boehringer Ingelheim and nonprofit group Cancer Care launched a tool designed to make cancer care social.
Healthcare data firm WorldOne has acquired Sermo
EvaluatePharma named Debbie Paul to the position of CEO Americas, EvaluatePharma USA
McCann Healthcare Worldwide has changed its name to McCann Health, and five of its six US agencies rebranded
Havas is adding Creative Lynx to its Havas Worldwide Health network of healthcare agencies.
News on Publicis, Omincom and Double Helix
It was once thought bizarre to foist a commitment to innovation on a regulatory agency. No longer!
A new report from the House Committee on Oversight and Government Reform blames FDA for shortages of generic injectable medications.
A Yale assistant professor and a medical student have provided evidence that FDA's review process is faster than those in other countries.
General Electric converted all of its 300,000+ employees and dependents to HDHPs
Remaining a step ahead of these shifts may prove the difference between leaders and followers
Adam Kline, EVP, Group Creative Director at JUICE Pharma Worldwide.
At Work With
Augé Reichenberg, Executive Creative Director for Healthcare, Rosetta
Ed Cowen, EVP, Managing Director, Medicus International New York
Industry, agency and media hires and promotions
Name That Brand
Brand X breaks sales boundaries
For pharma to truly unlock the power of the iPad, we need to evolve the way we look at it
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.